Literature DB >> 11406618

Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes.

A Lakkaraju1, J M Dubinsky, W C Low, Y E Rahman.   

Abstract

The potential of anionic liposomes for oligonucleotide delivery was explored because the requirement for a net-positive charge on transfection-competent cationic liposome-DNA complexes is ambiguous. Liposomes composed of phosphatidylglycerol and phosphatidylcholine were monodisperse and encapsulated oligonucleotides with 40-60% efficiency. Ionic strength, bilayer charge density, and oligonucleotide chemistry influenced encapsulation. To demonstrate the biological efficacy of this vector, antisense oligonucleotides to p53 delivered in anionic liposomes were tested in an in vitro model of excitotoxicity. Exposure of hippocampal neurons to glutamate increased p53 protein expression 4-fold and decreased neuronal survival to approximately 35%. Treatment with 1 microm p53 antisense oligonucleotides in anionic liposomes prevented glutamate-induced up-regulation of p53 and increased neuronal survival to approximately 75%. Encapsulated phosphorothioate p53 antisense oligonucleotides were neuroprotective at 5-10-fold lower concentrations than when unencapsulated. Replacing the anionic lipid with phosphatidylserine significantly decreased neuroprotection. p53 antisense oligonucleotides complexed with cationic liposomes were ineffective. Neuroprotection by p53 antisense oligonucleotides in anionic liposomes was comparable with that by glutamate receptor antagonists and a chemical inhibitor of p53. Anionic liposomes were also capable of delivering plasmids and inducing transgene expression in neurons. Anionic liposome-mediated internalization of Cy3-labeled oligonucleotides by neurons and several other cell lines demonstrated the universal applicability of this vector.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406618     DOI: 10.1074/jbc.M100138200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  p53-dependent cell death signaling in neurons.

Authors:  Richard S Morrison; Yoshito Kinoshita; Mark D Johnson; Weiqun Guo; Gwenn A Garden
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

2.  siRNA Therapeutics for Protein Misfolding Diseases of the Central Nervous System.

Authors:  Mark D Zabel; Luke Mollnow; Heather Bender
Journal:  Methods Mol Biol       Date:  2021

3.  Lipopeptide Delivery of siRNA to the Central Nervous System.

Authors:  Mark D Zabel; Luke Mollnow; Heather Bender
Journal:  Methods Mol Biol       Date:  2019

4.  Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA.

Authors:  Mengjie Rui; Hailing Tang; Yan Li; Xiaohui Wei; Yuhong Xu
Journal:  Pharm Res       Date:  2012-12-14       Impact factor: 4.200

Review 5.  DNA-based therapeutics and DNA delivery systems: a comprehensive review.

Authors:  Siddhesh D Patil; David G Rhodes; Diane J Burgess
Journal:  AAPS J       Date:  2005-04-08       Impact factor: 4.009

Review 6.  p53: twenty five years understanding the mechanism of genome protection.

Authors:  M Gomez-Lazaro; F J Fernandez-Gomez; J Jordán
Journal:  J Physiol Biochem       Date:  2004-12       Impact factor: 4.158

7.  Anionic liposomal delivery system for DNA transfection.

Authors:  Siddhesh D Patil; David G Rhodes; Diane J Burgess
Journal:  AAPS J       Date:  2004-10-15       Impact factor: 4.009

8.  Polymorphism of DNA-anionic liposome complexes reveals hierarchy of ion-mediated interactions.

Authors:  Hongjun Liang; Daniel Harries; Gerard C L Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

9.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

10.  Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes.

Authors:  Heather R Bender; Sarah Kane; Mark D Zabel
Journal:  J Vis Exp       Date:  2016-07-23       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.